Katakkar S B, Franks C R
Cancer Treat Rep. 1978 Sep;62(9):1379-80.
In a phase II study, eight patients with metastatic renal cell carcinoma have been treated with a combination of chemotherapy and hormonal therapy using adriamycin, hydroxyurea, vinblastine, and medroxyprogesterone acetate. Five patients have responded, including one with complete response, one with subjective improvement, and three with partial responses. The median survival was 4 months with a range of 4--11 months. With the exception of mild alopecia and nausea, toxicity was minimal; no significant hematologic toxicity was noted. The initial results of this study suggest that chemo-hormonal therapy plays a significant role in the management of renal cell carcinoma.
在一项II期研究中，8例转移性肾细胞癌患者接受了联合化疗和激素治疗，使用的药物有阿霉素、羟基脲、长春碱和醋酸甲羟孕酮。5例患者有反应，包括1例完全缓解、1例主观改善和3例部分缓解。中位生存期为4个月，范围为4至11个月。除轻度脱发和恶心外，毒性极小；未观察到明显的血液学毒性。这项研究的初步结果表明，化疗-激素疗法在肾细胞癌的治疗中发挥着重要作用。
